All In Biotech

Drug Trial Radar · NCT04410991

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 899 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

899

Actual

Start

Jun 11, 2020

Primary completion

Jul 16, 2024

Study completion Jul 16, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary Objective: To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance and quality of life To evaluate the safety and tolerability of daily SAR442168 To evaluate pharmacodynamics (PD) of SAR442168

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • TolebrutinibDrug

    Pharmaceutical form: Tablet Route of administration: Oral

  • Teriflunomide HMR1726Drug

    Pharmaceutical form: Tablet Route of administration: Oral

  • Placebo to match TolebrutinibDrug

    Pharmaceutical form: Tablet Route of administration: Oral

  • Placebo to match TeriflunomideDrug

    Pharmaceutical form: Tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated RelapsesTime frame: Baseline (Day 1) to approximately 48 months

Locations

186 sites in 28 countries. Site status is shown where the registry gives one.

  • North Central Neurology Associates, PC-Site Number:8400009

    Cullman, Alabama

  • Center for Neurology and Spine-Site Number:8400089

    Phoenix, Arizona

  • Arcadia Neurology Center-Site Number:8400070

    Arcadia, California

  • Multiple Sclerosis Center of California-Site Number:8400135

    Newport Beach, California

  • Harbor UCLA-Site Number:8400088

    Torrance, California

  • Mountain Neurological Research Center, Inc.-Site Number:8400128

    Basalt, Colorado

  • Advanced Neurosciences Research-Site Number:8400025

    Fort Collins, Colorado

  • South Florida Neurology Associates-Site Number:8400029

    Boca Raton, Florida

  • University of Florida Health-Site Number:8400159

    Gainesville, Florida

  • Neurology Associates, PA-Site Number:8400004

    Maitland, Florida

  • University of Miami-Site Number:8400063

    Miami, Florida

  • Infinity Clinical Research-Site Number:8400008

    Sunrise, Florida

  • University of South Florida-Site Number:8400006

    Tampa, Florida

  • Meridian Clinical Research-Site Number:8400003

    Savannah, Georgia

  • Consultants In Neurology-Site Number:8400011

    Northbrook, Illinois

  • Prairie Education and Research Cooperative-Site Number:8400071

    Springfield, Illinois

  • Fort Wayne Neurological Center-Site Number:8400039

    Fort Wayne, Indiana

  • CHI Saint Joseph Medical Group Neurology-Site Number:8400110

    Lexington, Kentucky

  • University of Kentucky-Site Number:8400106

    Lexington, Kentucky

  • Norton Neurology MS Services-Site Number:8400127

    Louisville, Kentucky

  • The NeuroMedical Center-Site Number:8400057

    Baton Rouge, Louisiana

  • International Neurorehabilitation Institute-Site Number:8400034

    Lutherville-Timonium, Maryland

  • Wayne State University-Site Number:8400046

    Detroit, Michigan

  • Minneapolis Clinic of Neurology-Site Number:8400051

    Minneapolis, Minnesota

  • Saint Luke's Hospital-Site Number:8400153

    Kansas City, Missouri

  • West Omaha Family Physicians-Site Number:8400139

    Omaha, Nebraska

  • University Of Nebraska-Site Number:8400129

    Omaha, Nebraska

  • Hackensack University Hospital-Site Number:8400047

    Hackensack, New Jersey

  • University of New Mexico-Site Number:8400032

    Albuquerque, New Mexico

  • South Shore Neurologic Associates-Site Number:8400100

    Patchogue, New York

  • Novant Health Multiple Sclerosis Care Center - South Park-Site Number:8400120

    Charlotte, North Carolina

  • Meridian Clinical Research, LLC-Site Number:8400005

    Raleigh, North Carolina

  • Sanford Brain & Spine Center-Site Number:8400126

    Fargo, North Dakota

  • Dayton Center for Neurological Disorders-Site Number:8400081

    Centerville, Ohio

  • Jefferson Neurology Associates-Site Number:8400016

    Philadelphia, Pennsylvania

  • Premier Neurology-Site Number:8400069

    Greer, South Carolina

  • Advanced Neuroscience Center-Site Number:8400035

    Franklin, Tennessee

  • Sibyl Wray, MD, Neurology, PC-Site Number:8400007

    Knoxville, Tennessee

  • Mt Olympus Medical Research-Site Number:8400163

    Katy, Texas

  • Neurology Center of San Antonio-Site Number:8400036

    San Antonio, Texas

Showing 40 of 186 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.